What's New in Pediatric Melanoma: An Update from the APSA Cancer Committee.

[1]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Ferrari,et al.  BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma , 2018, Pediatric blood & cancer.

[3]  J. Tashiro,et al.  Incidence and outcomes of pediatric extremity melanoma: A propensity score matched SEER study. , 2018, Journal of pediatric surgery.

[4]  J. Geiger,et al.  Pediatric melanoma and aggressive Spitz tumors: a retrospective diagnostic, exposure and outcome analysis. , 2018, Translational pediatrics.

[5]  Carrie D. Patnode,et al.  Behavioral Counseling for Skin Cancer Prevention: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet] , 2018 .

[6]  J. Kirkwood,et al.  Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Lyman,et al.  Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary. , 2017, Journal of oncology practice.

[8]  B. Geoerger,et al.  Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. , 2017, European journal of cancer.

[9]  J. Hardwicke,et al.  Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - A systematic review of the literature. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[11]  S. Swetter,et al.  State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now , 2016, CA: a cancer journal for clinicians.

[12]  E. Weiderpass,et al.  Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Elmore,et al.  The utilization of spitz‐related nomenclature in the histological interpretation of cutaneous melanocytic lesions by practicing pathologists: results from the M‐Path study , 2016, Journal of cutaneous pathology.

[14]  L. Elting,et al.  Health Disparities Influence Childhood Melanoma Stage at Diagnosis and Outcome. , 2016, The Journal of pediatrics.

[15]  J. Gattuso,et al.  Feasibility of Pegylated Interferon in Children and Young Adults With Resected High‐Risk Melanoma , 2016, Pediatric blood & cancer.

[16]  T. Sarantou,et al.  Pediatric and Adolescent Melanoma: A National Cancer Data Base Update , 2016, Annals of Surgical Oncology.

[17]  C. Berking,et al.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[18]  R. Turrisi,et al.  Effectiveness of a Multicomponent Sun Protection Program for Young Children: A Randomized Clinical Trial. , 2016, JAMA pediatrics.

[19]  D. R. Lewis,et al.  Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “nonmalignant/noninvasive” tumors , 2016, Cancer.

[20]  K. Delman,et al.  The importance of surgical margins in melanoma , 2016, Journal of surgical oncology.

[21]  J. Thomas,et al.  Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial , 2016, The Lancet. Oncology.

[22]  P. Mosca,et al.  Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. , 2015, Journal of pediatric surgery.

[23]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[24]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[25]  J. Barnholtz-Sloan,et al.  Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States. , 2015, The Journal of pediatrics.

[26]  O. Gefeller,et al.  443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. , 2015, European journal of cancer.

[27]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[28]  N. Hayward,et al.  Genetics of familial melanoma: 20 years after CDKN2A , 2015, Pigment cell & melanoma research.

[29]  J. King,et al.  Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001–2009 , 2014, Pediatrics.

[30]  Li Ding,et al.  The Genomic Landscape of Childhood and Adolescent Melanoma , 2014, The Journal of investigative dermatology.

[31]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[32]  D. Jukic,et al.  Pediatric melanoma: Analysis of an international registry , 2013, Cancer.

[33]  J. Cormier,et al.  Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. , 2013, Journal of pediatric surgery.

[34]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Kashani-Sabet,et al.  Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. , 2013, Journal of the American Academy of Dermatology.

[36]  A. Hauschild,et al.  Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. , 2013, Critical reviews in oncology/hematology.

[37]  C. Warneke,et al.  Complications in the surgical treatment of pediatric melanoma. , 2012, Journal of pediatric surgery.

[38]  D. McCready,et al.  Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[39]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[40]  R. Dummer,et al.  Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.

[41]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[43]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[44]  M. Ross,et al.  Outcomes in Pediatric Melanoma: Comparing Prepubertal to Adolescent Pediatric Patients , 2011, Annals of surgery.

[45]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[46]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[47]  S. Swetter,et al.  Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults—The Stanford Experience 1995–2008 , 2010, Pediatric dermatology.

[48]  W. Hohenberger,et al.  Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[49]  D. Jukic,et al.  Melanoma in pediatric, adolescent, and young adult patients. , 2009, Seminars in oncology.

[50]  Kurt Straif,et al.  A review of human carcinogens--part D: radiation. , 2009, The Lancet. Oncology.

[51]  D. Tyler,et al.  Pediatric melanoma: a single-institution experience of 150 patients. , 2009, Journal of pediatric surgery.

[52]  M. Ross,et al.  A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. , 2009, Journal of the American College of Surgeons.

[53]  P. Kam,et al.  Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma , 2009, Cancer.

[54]  A. Cochran,et al.  The rationale for sentinel-node biopsy in primary melanoma , 2008, Nature Clinical Practice Oncology.

[55]  M. Mihm,et al.  Melanoma in the young: Differences and similarities with adult melanoma , 2007, Cancer.

[56]  C. Balch,et al.  Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Pappo,et al.  Use of Sentinel Lymph Node Biopsy and High-dose Interferon in Pediatric Patients With High-risk Melanoma: The Hospital for Sick Children Experience , 2006, Journal of pediatric hematology/oncology.

[60]  M. Atkins,et al.  Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.

[61]  J. Ingle,et al.  Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma , 2006, Cancer.

[62]  B. Bastian,et al.  Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool , 2006, Dermatologic therapy.

[63]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[64]  T. Fears,et al.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Jennifer L. Schwartz,et al.  High‐risk surgically resected pediatric melanoma and adjuvant interferon therapy , 2005, Pediatric blood & cancer.

[66]  A. Pappo,et al.  The feasibility of adjuvant interferon α‐2b in children with high‐risk melanoma , 2005 .

[67]  P. Kam,et al.  Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion , 2004, Journal of surgical oncology.

[68]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[69]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[70]  J. Thomas,et al.  Excision margins in high-risk malignant melanoma. , 2004, The New England journal of medicine.

[71]  A. Pappo.  Melanoma in children and adolescents. , 2003, European journal of cancer.

[72]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[73]  M. Lens,et al.  Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. , 2003, The Lancet. Oncology.

[74]  D. McCready,et al.  Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity , 2003, Journal of surgical oncology.

[75]  P. Kam,et al.  Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma , 2002, Annals of Surgical Oncology.

[76]  N. Martin,et al.  Melanoma in adolescents: A case‐control study of risk factors in Queensland, Australia , 2002, International journal of cancer.

[77]  N. Cascinelli,et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.

[78]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  M. Tucker,et al.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[84]  C. Balch,et al.  Thin Stage I Primary Cutaneous Malignant Melanoma , 1988 .

[85]  Mcbride Cm,et al.  Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. , 1982 .

[86]  Jennifer M. Taber,et al.  Interdisciplinary Perspectives on Sun Safety. , 2018, JAMA dermatology.

[87]  E. Beierle,et al.  Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma , 2017, JAMA otolaryngology-- head & neck surgery.

[88]  J. Aldrink,et al.  Pediatric melanoma. , 2016, Seminars in pediatric surgery.

[89]  V. Sondak,et al.  Pediatric Melanoma and Atypical Melanocytic Neoplasms. , 2016, Cancer treatment and research.

[90]  R. Boldrini,et al.  Atypical Spitz tumors in patients younger than 18 years. , 2015, Journal of the American Academy of Dermatology.

[91]  A. Pappo.  Pediatric melanoma: the whole (genome) story. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[92]  S. Mocellin,et al.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.

[93]  H. Shaw,et al.  Sentinel node mapping for melanoma: results of trials and current applications. , 2007, Surgical oncology clinics of North America.

[94]  J. Kirkwood,et al.  Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  D. Krag,et al.  Lymphoscintigraphy and Sentinel Node Biopsy Accurately Stage Melanoma in Patients Presenting After Wide Local Excision , 2003, Annals of Surgical Oncology.

[96]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  C. Chastang,et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.

[98]  B. Brown,et al.  Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. , 1982, Surgery.